Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early use of evolocumab in cath lab for acute myocardial infarction
ChiCTR2200059319Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in myocardial infarction (MI) (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Change in lipid parameters. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2200059319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059319.